ATE432472T1 - Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren - Google Patents

Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren

Info

Publication number
ATE432472T1
ATE432472T1 AT99941990T AT99941990T ATE432472T1 AT E432472 T1 ATE432472 T1 AT E432472T1 AT 99941990 T AT99941990 T AT 99941990T AT 99941990 T AT99941990 T AT 99941990T AT E432472 T1 ATE432472 T1 AT E432472T1
Authority
AT
Austria
Prior art keywords
endogenous
constitutively activated
protein coupled
orphan receptors
coupled orphan
Prior art date
Application number
AT99941990T
Other languages
German (de)
English (en)
Inventor
Dominic Behan
Derek Chalmers
Chen Liaw
I-Lin Lin
Kevin Lowitz
Ruoping Chen
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of ATE432472T1 publication Critical patent/ATE432472T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/42Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99941990T 1998-07-31 1999-07-30 Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren ATE432472T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9487998P 1998-07-31 1998-07-31
US10630098P 1998-10-30 1998-10-30
US11090698P 1998-12-04 1998-12-04
US12185199P 1999-02-26 1999-02-26
PCT/US1999/017425 WO2000006597A2 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Publications (1)

Publication Number Publication Date
ATE432472T1 true ATE432472T1 (de) 2009-06-15

Family

ID=27492754

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99941990T ATE432472T1 (de) 1998-07-31 1999-07-30 Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren

Country Status (13)

Country Link
EP (1) EP1095275B1 (enExample)
JP (1) JP2002521681A (enExample)
CN (1) CN1231762C (enExample)
AT (1) ATE432472T1 (enExample)
AU (1) AU751080B2 (enExample)
CA (1) CA2338543C (enExample)
DE (1) DE69940923D1 (enExample)
DK (1) DK1095275T3 (enExample)
IL (1) IL140858A0 (enExample)
MX (1) MXPA01001176A (enExample)
NO (1) NO20010509L (enExample)
NZ (1) NZ509429A (enExample)
WO (1) WO2000006597A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
MXPA02009902A (es) 2000-04-07 2003-06-17 Arena Pharm Inc Receptores acoplados a proteina g, conocidos, activados constitutivamente, no endogenos.
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
WO2003081256A2 (en) * 2002-03-22 2003-10-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
WO2004015422A2 (en) * 2002-08-05 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
CA2511144A1 (en) * 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2005095990A1 (en) * 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220715C (en) * 1995-06-07 2004-11-02 Praecis Pharmaceuticals Incorporated Functional bioassay for g-protein coupled receptor agonists and antagonists
WO1997011159A1 (en) * 1995-09-20 1997-03-27 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
NZ336479A (en) * 1997-04-14 2001-10-26 Arena Pharm Inc A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease

Also Published As

Publication number Publication date
DK1095275T3 (da) 2009-09-28
JP2002521681A (ja) 2002-07-16
CN1323396A (zh) 2001-11-21
IL140858A0 (en) 2002-02-10
MXPA01001176A (es) 2005-07-25
NZ509429A (en) 2002-06-28
AU751080B2 (en) 2002-08-08
WO2000006597A9 (en) 2000-07-13
DE69940923D1 (de) 2009-07-09
NO20010509L (no) 2001-03-19
WO2000006597A2 (en) 2000-02-10
CA2338543A1 (en) 2000-02-10
EP1095275A2 (en) 2001-05-02
AU5545999A (en) 2000-02-21
WO2000006597A3 (en) 2000-05-18
CN1231762C (zh) 2005-12-14
EP1095275B1 (en) 2009-05-27
CA2338543C (en) 2009-12-29
NO20010509D0 (no) 2001-01-30

Similar Documents

Publication Publication Date Title
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
ATE227716T1 (de) 2-substituierte-1-piperidyl- benzimidazolverbindungen als orl1 rezeptor agonisten
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
NO20024221D0 (no) Blandinger inneholdende alfa-2-adrenerge agonistkomponenter
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
ATE344241T1 (de) Benzyliden-1,3-dihydro-indol-2-on-derivate als inhibitoren von rezeptor tyrosine kinasesn, insbesondere von raf kinasen
DK1261322T3 (da) Farmaceutiske sammensætninger omfattende en adenosinreceptoragonist eller antagonist
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
DE69728893T2 (de) N-aryl substituierte tetrahydrochinoline ligande für retinoidrezeptoren mit agonist, antagonist oder inverser agonist wirkung
EA200501724A1 (ru) Соединения, специфичные к меланокортиновым рецепторам
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
BRPI0410884A (pt) composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação
ATE540970T1 (de) Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
BR0007864A (pt) Composto, e, uso de um composto
ATE432472T1 (de) Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
CO5460266A1 (es) Novedosos analogos de la somatostatina
BR0318631A (pt) os agonistas receptores peptìdeo-1 similares ao glucagon, a preparação e o uso do mesmo
EA200500830A1 (ru) Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
BR0010882A (pt) Agonistas receptores de adenosina a1 oralmente ativos e processo para uso de tal composição
DK0862627T3 (da) Neuropeptid Y-Y5 receptor
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties